1. Home
  2. ALKS
  3. Earnings

AI Earnings Predictions for Alkermes plc (ALKS)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-0.44%

$46.09

0% positive prob.

5-Day Prediction

-4.24%

$44.33

0% positive prob.

20-Day Prediction

-3.39%

$44.72

0% positive prob.

Price at prediction: $46.29 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -0.44% -4.24% -3.39% 100.0% Pending
Q2 2026 BUY +1.23% +3.91% +5.80% 100.0% Pending
Q1 2026 BUY +1.70% +3.70% +4.28% 100.0% +5.63%
Q4 2025 SELL +0.05% -4.06% -3.04% 86.2% -5.67%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 3, 2026 · 100% conf.

AI Prediction SELL

1D

-0.44%

$46.09

Act: +0.44%

5D

-4.24%

$44.33

20D

-3.39%

$44.72

Price: $46.29 Prob +5D: 0% AUC: 1.000
0001193125-26-444381

EX-99.1

2 alks-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Alkermes Contacts:

For Investors:

Sandy Coombs +1 781 609 6377

For Media:

Katie Joyce +1 781 249 8927

Alkermes plc Reports Third Quarter 2026 Financial Results

— Third Quarter Revenues of $480.1 Million —

— GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million —

— Company Reiterates 2026 Financial Expectations —

DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026.

“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder, further strengthens our leadership position in orexin-based research. As we continue to advance our orexin development portfolio, we are growing the body of evidence supporting the potential of orexin biology across multiple neuropsychiatric disorders and expect several important clinical data readouts over the year ahead. With a portfolio of development candidates in one of the most exciting new therapeutic categories in neuroscience and a steady cadence of clinical data readouts ahead, we believe we are well positioned to drive long-term value for shareholders.”

Key Financial Highlights

Revenues

Three Months Ended

September 30,

Nine Months Ended

September 30,

(In millions)

2026

2025

2026

2025

Total Revenues

$

480.1

$

394.2

$

1,369.1

$

1,091.4

Total Proprietary Net Sales

$

417.3

$

317.4

$

1,167.1

$

869.2

VIVITROL®

$

127.6

$

121.1

$

364.4

$

343.8

ARISTADA®i

$

103.9

$

98.1

$

294.4

$

272.8

LYBALVI®

$

95.9

$

98.2

$

282.2

$

252.6

LUMRYZ®

$

89.9

$

—

$

226.0

$

—

Profitability

Three Months Ended

September 30,

Nine Months Ended

September 30,

(In millions)

2026

2025

2026

2025

GAAP Net Income (Loss)

$

16.3

$

82.8

$

(49.7)

$

192.3

EBITDA

$

63.0

$

96.9

$

81.8

$

221.2

Adjusted EBITDA

$

120.1

$

121.5

$

339.5

$

293.7

Revenue Highlights

Proprietary Product Revenues

• VIVITROL revenues for the quarter were $127.6 million. During the quarter, the company recorded VIVITROL revenue of approximately $8 million related to gross-to-net favorability, primarily driven by favorable patient mix.

1

• ARISTADAi revenues for the quarter were $103.9 million, which included approximately $4 million of inventory benefit related to timing of shipments. During the quarter, the company recorded ARISTADA revenue of approximately $3 million related to gross-to-net favorability, primarily driven by favorable patient mix.

• LYBALVI revenues for the quarter were $95.9 million, which included approximately $2 million of inventory benefit related to timing of shipments. Total prescriptions grew 18% compared to the third quarter of 2025.

• LUMRYZ revenues for the quarter were $89.9 million. At the end of the third quarter, approximately 4,100 patients were on LUMRYZ therapy.

Manufacturing & Royalty Revenues

• VUMERITY® manufacturing and royalty revenues for the quarter were $29.5 million.

• Royalty revenue from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the quarter were $26.4 million.

Key Operating Expenses

Three Months Ended

September 30,

(In millions)

2026

GAAP

2026

Transaction Adjustments

2026

Non-GAAP

Adjusted

2025

GAAP

Cost of Goods Sold

$

94.2

$

28.7

$

65.6

$

51.6

R&D Expense

$

121.1

$

0.1

$

121.0

$

81.7

SG&A Expense

$

208.5

$

1.0

$

207.5

$

171.8

Nine Months Ended

September 30,

(In millions)

2026

GAAP

2026

Transaction Adjustments(1)

2026

Non-GAAP

Adjusted

2025

GAAP

Cost of Goods Sold

$

253.9

$

72.4

$

181.5

$

150.2

R&D Expense

$

337.4

$

8.3

$

329.1

$

230.9

SG&A Expense

$

690.7

$

57.6

$

633.1

$

514.3

(1) Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Avadel) employees which vested in full upon the closing of the transaction.

Balance Sheet

• At Sept. 30, 2026, the company recorded cash, cash equivalents and total investments of $787.6 million, compared to $691.6 million at June 30, 2026.

Financial Expectations for 2026

Alkermes reiterates its financial expectations for 2026, as set forth in its press release dated July 28, 2026.

Conference Call

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’

2026
Q2

Q2 2026 Earnings

8-K BUY

Jul 28, 2026 · 100% conf.

AI Prediction BUY

1D

+1.23%

$52.48

Act: -4.28%

5D

+3.91%

$53.87

20D

+5.80%

$54.85

Price: $51.84 Prob +5D: 100% AUC: 1.000
0001193125-26-318844

EX-99.1

2 alks-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Alkermes Contacts:

For Investors:

Sandy Coombs +1 781 609 6377

For Media:

Katie Joyce +1 781 249 8927

Alkermes plc Reports Second Quarter 2026 Financial Results

— Second Quarter Revenues of $496.0 Million —

— GAAP Net Income of $0.5 Million and Adjusted EBITDA of $139.2 Million —

— Blair Jackson to Assume Chief Executive Officer Role on August 1, 2026; Richard Pops to Continue as Chairman of the Board of Directors —

DUBLIN, July 28, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2026.

“The second quarter was marked by strong commercial performance and meaningful progress across our pipeline as we continued to execute on our strategic priorities. Our commercial portfolio consists of differentiated products that are positioned to generate substantial revenue and cash flow for years to come. At the same time, our orexin 2 receptor agonist portfolio represents a potentially transformational growth opportunity for Alkermes and positions us at the forefront of one of the most exciting new therapeutic categories in neuroscience,” said Richard Pops, Chairman and Chief Executive Officer of Alkermes. “As I prepare to transition the Chief Executive Officer role, I do so with tremendous pride in what this organization has achieved and great optimism for its future. Blair and the leadership team are well positioned to build on this momentum and lead Alkermes through its next phase of growth, innovation and value creation, and I look forward to supporting them in my continuing role as Chairman.”

“As we move into the second half of the year, we have clear priorities and a sharp focus on execution. With our first ADHD data for ALKS 7290 expected in the coming months and topline results from our alixorexton phase 2 idiopathic hypersomnia study expected toward year-end, we are generating significant new datasets that may open new opportunities for our orexin 2 receptor portfolio,” said Blair Jackson, Chief Operating Officer of Alkermes. “With a talented team, a strong financial foundation and exciting opportunities ahead in sleep medicine and across our neuroscience portfolio, I am honored to step into the CEO role and continue building on the strong foundation for growth that Richard and the entire organization have established.”

Key Financial Highlights

Revenues

Three Months Ended

June 30,

Six Months Ended

June 30,

(In millions)

2026

2025

2026

2025

Total Revenues

$

496.0

$

390.7

$

888.9

$

697.2

Total Proprietary Net Sales

$

411.7

$

307.2

$

749.8

$

551.7

VIVITROL®

$

124.5

$

121.7

$

236.9

$

222.7

ARISTADA®i

$

96.7

$

101.3

$

190.5

$

174.8

LYBALVI®

$

94.0

$

84.3

$

186.3

$

154.3

LUMRYZ®

$

96.6

$

—

$

136.1

$

—

Profitability

Three Months Ended

June 30,

Six Months Ended

June 30,

(In millions)

2026

2025

2026

2025

GAAP Net (Loss) Income

$

0.5

$

87.1

$

(66.0)

$

109.6

EBITDA

$

49.0

$

101.6

$

18.8

$

124.3

Adjusted EBITDA

$

139.2

$

126.5

$

219.5

$

172.1

1

Revenue Highlights

Proprietary Product Revenues

• LYBALVI revenues for the quarter were $94.0 million. Revenues and total prescriptions grew 12% and 18%, respectively, compared to the second quarter of 2025.

• ARISTADAi revenues for the quarter were $96.7 million. During the quarter, the company recorded ARISTADA revenue of approximately $4 million related to gross-to-net favorability, primarily driven by favorable patient mix.

• VIVITROL revenues for the quarter were $124.5 million. During the quarter, the company recorded VIVITROL revenue of approximately $4 million related to gross-to-net favorability, primarily driven by favorable patient mix.

• LUMRYZ revenues for the quarter were $96.6 million, which included approximately $7 million of inventory benefit due to timing of shipments.

Manufacturing & Royalty Revenues

• VUMERITY® manufacturing and royalty revenues for the quarter were $30.6 million.

• Royalty revenue from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the quarter were $27.5 million.

• Manufacturing revenue from RISPERDAL CONSTA® for the quarter was $20.9 million.

Key Operating Expenses

Three Months Ended

June 30,

(In millions)

2026

GAAP

2026

Transaction Adjustments

2026

Non-GAAP

Adjusted

2025

GAAP

Cost of Goods Sold

$

98.1

$

31.0

$

67.1

$

49.5

R&D Expense

$

112.9

$

0.1

$

112.8

$

77.4

SG&A Expense

$

217.6

$

1.3

$

216.3

$

170.8

Six Months Ended

June 30,

(In millions)

2026

GAAP

2026

Transaction Adjustments(1)

2026

Non-GAAP

Adjusted

2025

GAAP

Cost of Goods Sold

$

159.7

$

43.8

$

115.9

$

98.7

R&D Expense

$

216.3

$

8.2

$

208.1

$

149.2

SG&A Expense

$

482.2

$

56.6

$

425.6

$

342.6

(1) Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Av

2026
Q1

Q1 2026 Earnings

8-K BUY

May 5, 2026 · 100% conf.

AI Prediction BUY

1D

+1.70%

$36.87

Act: -2.57%

5D

+3.70%

$37.59

Act: +5.63%

20D

+4.28%

$37.80

Act: +17.96%

Price: $36.25 Prob +5D: 100% AUC: 1.000
0001193125-26-205008

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784470094.ec62c2a1

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About Alkermes plc (ALKS) Earnings

This page provides Alkermes plc (ALKS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ALKS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: